Certara(NASDAQ) CERT

Certara helps drug companies test new medicines using computer simulations. This technology lets scientists see how drugs work before testing them on people. These tools help get safe medicines to patients faster and at lower costs.

Tools for Better Medicines

• Simcyp Simulator: Mechanistic biosimulation platform that predicts how drugs behave in humans; helps set doses and avoid side effects.
• Phoenix PK/PD: Software suite for managing and analyzing clinical trial data; includes the industry-standard WinNonlin and NLME modules.
• Pinnacle 21: Cloud-based tool that checks if clinical data meets standards for government submission; used by major drug regulators.
• CoAuthor Software: Uses artificial intelligence to help scientists write the complex reports required for regulatory drug approvals.
• Chemaxon: Scientific informatics software used for predicting chemical properties and analyzing leads during early drug discovery.

Building the Science Platform

• Acquired Chemaxon in 2024 to add chemical search and analysis tools for early-stage drug discovery.
• Purchased Formedix and Applied Biomath in 2023 to expand clinical data automation and biological modeling.
• Integrated Vyasa technology to bring advanced artificial intelligence capabilities to its software portfolio.
• Launched Certara.AI in 2023 to help researchers find and create scientific content using generative pre-trained transformers.

What Makes Certara Different?

Certara technology was used by customers in 90% of all novel drug approvals by the FDA between 2014 and 2025. The company maintains an international footprint with operations in 28 countries and software used by 20 global regulatory agencies.

A Look at the Numbers

• Revenue reached $103.6 million in Q4 2025, up 3.3% from $100.4 million in Q4 2024.
• Operating income was $836,000 in Q4 2025, down 86.1% from $6 million the previous year.
• Net income reached -$5.9 million in Q4 2025, worsening from $6.6 million in Q4 2024.
• Free cash flow hit $27.8 million in Q4 2025, down 36.1% from $43.5 million in Q4 2024.

The Path Ahead

Certara has evolved from a specialized software provider into a broad platform for drug development and regulatory science. Its combination of simulation technology and AI tools positions it at the center of modern pharmaceutical research.